entecavir / Generic mfg. - LARVOL DELTA

Tenofovir disoproxil fumarate: safe and effective option for managing high-viral-load chronic hepatitis B. (PubMed, Am J Transl Res) - "These findings suggest that TDF is more effective than ETV for treating high-viral-load CHB patients."

Journal • Hepatitis B • Infectious Disease • Inflammation

Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial. (PubMed, J Clin Transl Hepatol) - "Our Phase 2 trial of hydronidone for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis showed that adding hydronidone to entecavir resulted in significant reversal of liver fibrosis...The primary endpoint of the trial is to demonstrate the efficacy of fibrosis reversal, defined as a decrease in the Ishak stage score of liver fibrosis by ≥1 after 52 weeks of treatment, compared to baseline. The results of this trial are expected to further support the antifibrotic indication for this novel drug."

Journal • P3 data • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

HYPOPROTHROMBINEMIA SECONDARY TO LUPUS ANTICOAGULANT A (LA-HPS): CASE REPORT (EHA 2025) - "HBV-positive (Entecavir). Alveolar hemorrhages (1997) with positive AF and ANA, since then immunosuppressive treatment (IS), currently Prednisone...Given the need for surgery, treatment was started to try to optimize coagulation: Konakion EV 10 miligrams each 12 hours (3 days), IVIG 0.4 gr/kg/day (4 days) and Dexamethasone (oral) 40 mg each 24 hours, 4 days... LA-HPS is rare entity but it is one of the 2 situations in which LA can be associated with a greater bleeding risk than thrombotic risk: the other is when it´s associated with thrombocytopenia. Mean age of presentation is 10 years but it may occur later, Although our patient is male, incidence is higher in women (4:1). As in our patient, he could present with hemorrhagic symptoms at different levels, for whose treatment different measures can be used (Corticoesteroides, IVIG, Antifibrinolytics, Prothrombin Complex Concentrate)."

Case report • Clinical • Cardiovascular • Hematological Disorders • Immunology • Inflammatory Arthritis • Peripheral Arterial Disease • Thrombocytopenia • Thrombosis

Infliximab may contribute to remit rapidly progressive of IgA nephropathy secondary to Crohn's disease: A case report. (PubMed, Technol Health Care) - "Many novel therapies, such as anti-TNFα therapy, have been shown to influence IgAN while controlling IBD.Case presentationA 52-year-old woman had been treated with infliximab and azathioprine for Crohn's disease, and taking entecavir for hepatitis B. Recently, the patient developed gross hematuria, acute renal insufficiency, and positive blood anti-GBM antibody after the exacerbation of Crohn's disease. However, anti-TNF-α therapy may promote the remission of hematuria and renal insufficiency by inhibiting the inflammatory response in renal tissues. Therefore, more studies are needed to understand the specific role of anti-TNFα therapy in IgAN."

Journal • Review • Acute Kidney Injury • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • Hepatitis B • IgA Nephropathy • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Lupus Nephritis • Nephrology • Oncology • Renal Disease

Predictive factors and clinical outcomes in decompensated non-cirrhotic chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate. (PubMed, J Formos Med Assoc) - "The presence of ascites and hepatic encephalopathy, baseline HBV DNA levels, and MELD scores were associated with short-term and long-term all-cause mortality. Additionally, lower HBV DNA levels and higher ALT levels at baseline were independently predictive of sequential HBsAg seroclearance."

Biomarker • Clinical data • Journal • CNS Disorders • Hepatic Encephalopathy • Hepatitis B • Infectious Disease • Inflammation • Liver Failure • Transplantation

Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers (clinicaltrials.gov) - P3 | N=136 | Recruiting | Sponsor: Sun Yat-sen University

New P3 trial • Gastrointestinal Cancer • Hepatitis B • Infectious Disease • Oncology • Solid Tumor

Juvenile Dermatomyositis and Hepatitis B Viral Infection. (PubMed, Eur J Case Rep Intern Med) - "Rare case insight highlights the difficulties in diagnosing autoimmune and viral disorders by presenting a rare case of concurrent juvenile dermatomyositis and chronic hepatitis B infection.Lessons in clinical management emphasizes the significance of controlling the risk of viral reactivation and screening for hepatitis B prior to immunosuppressive treatment.Multidisciplinary and educational value highlights the importance of a multidisciplinary approach and provides internists with useful knowledge on how to provide individualized care in complicated rheumatic situations."

Journal • Dermatomyositis • Hepatitis B • Hepatocellular Cancer • Immunology • Infectious Disease • Inflammation • Myositis • Oncology • Solid Tumor

EFFICACY AND SAFETY OF TENOFOVIR PLUS ENTECAVIR COMBINATION THERAPY VERSUS TENOFOVIR MONOTHERAPY IN CHRONIC HBV PATIENTS WITH RESISTANCE TO ENTECAVIR: A SYSTEMATIC REVIEW AND META-ANALYSIS (DDW 2025) - "Tenofovir disoproxil fumarate (TDF) monotherapy and entecavir plus tenofovir (TDF+ETV) combination therapy are both employed as treatments, but one's efficacy over another is in question. CONCLUSION DF+ETV shows slightly better efficacy to TDF monotherapy over a 48-week treatment regimen, with minimal safety concerns. However, further high-quality studies like randomised controlled trials are needed to further solidify conclusions, with this meta-analysis only achieving borderline significance."

Combination therapy • Monotherapy • Retrospective data • Review • Hepatitis B • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor

EFFICACY AND SAFETY OF TREATMENTS FOR CHRONIC HEPATITIS D: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 19 RANDOMIZED CONTROLLED TRIALS (DDW 2025) - "Objective: This meta-analysis evaluates the efficacy and safety of pharmacological treatments for chronic HDV, including Lamivudine, Peg-IFN, Ribavirin, IFN alfa-2a, Adefovir, Bulevirtide, Lonafarnib, TDF, and Entecavir... Bulevirtide with Peg-IFN is the most effective and safest treatment for chronic HDV, particularly in cirrhotic patients. TDF shows potential but requires further study in larger, long-term trials. Adverse effects from therapies like Peg-IFN and Lonafarnib emphasize the need for careful monitoring."

Retrospective data • Review • Anemia • Fatigue • Gastrointestinal Disorder • Hematological Disorders • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis • Pain

EVALUATING THE USE OF HEPATITIS B IMMUNOGLOBULIN POST LIVER TRANSPLANT (DDW 2025) - "1 was taking entecavir, but was later found to be positive for hepatitis D, hence HBIG was continued...3 patients developed recurrence of HBsAg on lamivudine. These patients could be changed to tenofovir and have their HBIG ceased with monitoring as per protocol. This project demonstrates that patients receiving HBIG therapy should be more regularly reviewed for consideration of cessation in line with the guidelines."

Biliary Cancer • Cholangiocarcinoma • Fibrosis • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Oncology • Solid Tumor • Transplantation

Serum hepatitis B virus RNA in low-level viremia of chronic hepatitis B: clinical features and association with virological response. (PubMed, Virol J) - "In children with LLV, serum HBV RNA level is an independent risk factor for non-virological response and may serve as a complementary biomarker to HBV DNA for guiding antiviral therapy adjustments."

Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pediatrics

Pien Tze Huang plus entecavir improves hepatic fibrosis in Chinese patients with chronic hepatitis B. (PubMed, Phytomedicine) - P4 | "The combination of PTH and entecavir demonstrates significant improvement in hepatic fibrosis among CHB patients, especially those who are treatment-naive patients."

Clinical • Journal • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation

Epidural Abscess: An Uncommon Presentation of Tuberculosis in a Young African Male (ATS 2025) - "Infectious diseases recommended Rifampin, Isoniazid, Pyrazinamide, Ethambutol, and vitamin B6. Patient was also discharged on Entecavir.DiscussionEpidural abscess is an uncommon pathology that needs urgent intervention...Radiological assessment is paramount. Patients with a tubercular epidural abscess will need drainage, decompression, and a complete course of anti-tuberculous therapy."

Back Pain • CNS Disorders • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Respiratory Diseases • Tuberculosis • CRP

Dual therapy with nucleos(t)ide analogues in the prevention of hepatitis B virus recurrence after liver transplantation: Two case reports. (PubMed, World J Hepatol) - "These cases suggest the efficacy of dual NA therapy in post-transplant HBV management, emphasizing the need to reconsider traditional treatment approaches."

Journal • Fibrosis • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Oncology • Respiratory Diseases • Solid Tumor • Transplantation

Impacts of PEG-IFN-α-2b Combination Therapy on Liver Function, Immune Factors and Risk Factors in Patients With HBV Infection: A Retrospective Study. (PubMed, Br J Hosp Med (Lond)) - "This study aimed to explore the efficacy of PEG-IFNα-2b combined with entecavir in the treatment of HBV infection, its effect on liver function and immune factors, and the risk factors affecting the prognosis of patients with HBV infection...Conclusion The PEG-IFNα-2b combination therapy in patients with HBV infection significantly improves the clinical treatment efficacy, liver function, and immune factors. In addition, this study found that therapy regimen and family medical history are independent factors affecting the prognosis of HBV infection."

Journal • Retrospective data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Oncology • IFNA1 • IFNG • TNFA

Lower Muscle Area and Immunosuppressive Agents are Associated with Greater Bone Loss in Liver Transplant Recipients (ENDO 2025) - "Corticosteroids and tacrolimus were used in most patients post-transplant (98.08% each), followed by mycophenolate (81.47%), mTOR inhibitors (46.33%), and cyclosporine (33.55%). Of 117 HBV patients, 47% were treated with entecavir and 42% were treated with tenofovir...Higher tacrolimus doses, lower mycophenolate doses, and low muscle area were found to have the most significant impact on BMD decline.As one of the first large-scale, longitudinal, multidimensional studies in this field, the SiLVER study has the potential to provide valuable insights to guide evidence-based strategies for improving musculoskeletal health and optimizing perioperative and postoperative care.*. .*"

Clinical • Fibrosis • Gastroenterology • Hepatitis B • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Musculoskeletal Diseases • Osteoporosis • Rheumatology • Sarcopenia • Transplantation

Entecavir for children and adults with chronic hepatitis B. (PubMed, Cochrane Database Syst Rev) - "Given the issues of risk of bias and insufficient power of the included trials and the very low certainty of the available evidence, we could not determine the effect of entecavir versus no treatment or placebo on critical outcomes such as all-cause mortality and serious adverse events. There is a lack of data on health-related quality of life. Given the first-line recommendation and wide usage of entecavir in people with chronic hepatitis B, further evidence on clinically important outcomes, analysed in this review, is needed."

Clinical • Journal • Review • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Combination treatment of TLR7 agonist and anti-PD-L1 reconstitute protective immunity in virally suppressed chronic hepatitis B patients (EASL 2025) - " Totally 24 nucleos(t)ide analogues (NUCs)-treated CHB patients were randomized to receive Entecavir (ETV) monotherapy (n=6), ETV+TQA3334 dual therapy (n=9) or NA+TQA3334+TQB2450 triple therapy (n=9) for 24 weeks and then followed up for 24 weeks. The combination of TLR7 agonist and anti-PD-L1 could reconstitute antiviral immunity in virally suppressed CHB patients by inducing the production of ISGs, antiviral cytokines, and reinvigorating HBV-specific CD8+T cell response, thus potentially favouring improved clinical outcome."

Clinical • IO biomarker • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • CD8 • IFNA1 • IFNG • IL21 • ISG15 • MX1

Accelerated HBsAg reduction rate and increased proportion of HBsAg <100 IU/mL through repeated finite Nuc therapy in HBeAg-negative chronic hepatitis B patients (EASL 2025) - "During the first treatment, 70 patients used Entecavir, 8 used Tenofovir, and 10 used other Nucs (LAM, LdT)... Repeat finite therapy accelerates HBsAg reduction, significantly increases the proportion achieving HBsAg <100 IU/mL, with low HCC incidence, making it a considerable option for patients failing to achieve sustained response or functional cure after Nuc discontinuation."

Clinical • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Enhanced 2- and 3-Year recurrence-free survival rates with switching from Entecavir to Tenofovir post-radiofrequency ablation treatment in HBV-HCC patients (EASL 2025) - "This retrospective study aimed to compare the 3-year recurrence-free survival (RFS) rates among HBV- related HCC patients who switched from entecavir (ETV) to tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) after RFA with those who continued long-term ETV therapy. In HBV-HCC patients after RFA treatment, switching from ETV to NtAs (TDF or TAF) results in higher 2- and 3-year RFS rates compared to continuous NA therapy, indicating that NtAs may be superior to NAs in reducing the recurrence rate following curative treatment of HBV-related HCC."

Clinical • Fibrosis • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology

Functional cure of chronic HBV: natural history, determinants, and outcomes: a real-world experience from a tertiary liver center (EASL 2025) - "Treated patients (N=58) received TDF (35%), LAM (28%), or Entecavir (19%), and the mean therapy duration was 5.2 years (95% CI: 4.48–5.9)... Functional cure was observed in 8.0% of the cohort, a prevalence higher than that previously reported in the literature. This might be due to routine annual HBsAg testing for all patients. Most with functional cure were treatment-naïve."

Clinical • Real-world • Real-world evidence • Fibrosis • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Oncology • Solid Tumor

Impact of drugs for hepatocellular carcinoma development in chronic hepatitis B patients who treated with entecavir and tenofovir disoproxil as initial therapy: population-based study (EASL 2025) - "Background and Aims: Entecavir (ETV) and Tenofovir disoproxil fumarate (TDF) have been used as the first-line antiviral agents for patients with treatment-naive chronic hepatitis B (CHB), resulting in successful decline of hepatocellular carcinoma (HCC) development and mortality. In this study, TDF showed a more protective effect on HCC development compared to ETV. In addition, the use of statin and H1-antihistamines was independently associated with a lower risk of HCC development relative to no use of each drug. The effects of various drugs on the development of HCC were confirmed, and further research is needed on these mechanisms."

Clinical • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

Screening of different species reveals cat as a potential HBV infection model (EASL 2025) - "Antiviral drug testing included Myrcludex B, Entecavir, and poly IC. This study demonstrates for the first time that primary cat hepatocytes support HBV infection, providing a potential new platform for HBV basic and translational research. The use of cats as an animal model is being explored and may further advance HBV research and therapeutic development."

Hepatitis B • Hepatology • Infectious Disease • Inflammation

Treatment duration, adherence and persistence in patients with chronic hepatitis B virus infection treated with long-term nucleos(t)ide analogues in Germany (EASL 2025) - "Adult patients who initiated single-drug formulation second-generation NA treatment (entecavir, telbivudine, tenofovir disoproxil fumarate, and tenofovir alafenamide) between January 1, 2015–August 31, 2022, and had a recorded diagnosis for chronic HBV infection in the year prior to their initial NA prescription, were selected. Treatment discontinuation remains a key challenge in the management of chronic HBV infection. This study highlights the unmet need for additional support to help patients persist with NA treatment. These results also underscore the critical need for alternative therapies for chronic HBV infection with shorter and finite treatment durations with a reduced need for rigid monitoring to mitigate the high discontinuation rate while ensuring optimal clinical outcomes."

Adherence • Clinical • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

High FIB-4 index predicts liver decompensation in chronic hepatitis B patients who develop clinical relapse after antiviral therapy cessation (EASL 2025) - "These patients received entecavir (56%) and tenofovir (31%) for a median of 37 months before NA cessation... An EOT FIB-4 index of > 1.5 can help identify patients at a high risk of developing liver decompensation following CR. These patients should be closely monitored after NA discontinuation. Moreover, patients with a FIB-4 index > 4.4 at CR indicate an even greater risk and should receive prompt retreatment."

Clinical • Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Failure